bio-techne corp. - TECH

TECH

Close Chg Chg %
62.95 -1.03 -1.64%

Closed Market

61.92

-1.03 (1.64%)

Volume: 2.80M

Last Updated:

Oct 6, 2025, 4:00 PM EDT

Company Overview: bio-techne corp. - TECH

TECH Key Data

Open

$62.95

Day Range

61.50 - 63.10

52 Week Range

46.02 - 80.42

Market Cap

$9.79B

Shares Outstanding

155.55M

Public Float

153.75M

Beta

1.48

Rev. Per Employee

N/A

P/E Ratio

137.06

EPS

$0.46

Yield

50.83%

Dividend

$0.08

EX-DIVIDEND DATE

Aug 18, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

2.83M

 

TECH Performance

1 Week
 
0.00%
 
1 Month
 
15.70%
 
3 Months
 
18.46%
 
1 Year
 
-15.82%
 
5 Years
 
-5.01%
 

TECH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About bio-techne corp. - TECH

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

TECH At a Glance

Bio-Techne Corp.
614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Phone 1-612-379-8854 Revenue 1.22B
Industry Biotechnology Net Income 73.36M
Sector Health Technology 2025 Sales Growth 5.226%
Fiscal Year-end 06 / 2026 Employees 3,100
View SEC Filings

TECH Valuation

P/E Current 137.056
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 112.018
Price to Sales Ratio 6.738
Price to Book Ratio 4.155
Price to Cash Flow Ratio 28.58
Enterprise Value to EBITDA 23.424
Enterprise Value to Sales 6.969
Total Debt to Enterprise Value 0.052

TECH Efficiency

Revenue/Employee 393,430.645
Income Per Employee 23,665.484
Receivables Turnover 5.895
Total Asset Turnover 0.454

TECH Liquidity

Current Ratio 3.459
Quick Ratio 2.382
Cash Ratio 0.922

TECH Profitability

Gross Margin 63.875
Operating Margin 20.739
Pretax Margin 8.073
Net Margin 6.015
Return on Assets 2.732
Return on Equity 3.68
Return on Total Capital 3.105
Return on Invested Capital 3.041

TECH Capital Structure

Total Debt to Total Equity 23.142
Total Debt to Total Capital 18.793
Total Debt to Total Assets 17.36
Long-Term Debt to Equity 22.408
Long-Term Debt to Total Capital 18.197
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-techne Corp. - TECH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.11B 1.14B 1.16B 1.22B
Sales Growth
+18.75% +2.81% +1.97% +5.23%
Cost of Goods Sold (COGS) incl D&A
382.60M 366.89M 385.99M 440.59M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
101.07M 107.24M 111.71M 109.90M
Depreciation
26.92M 29.75M 31.86M 34.58M
Amortization of Intangibles
74.15M 77.49M 79.85M 75.32M
COGS Growth
+17.15% -4.11% +5.21% +14.15%
Gross Income
723.00M 769.82M 773.07M 779.04M
Gross Income Growth
+19.61% +6.48% +0.42% +0.77%
Gross Profit Margin
+65.39% +67.72% +66.70% +63.88%
2022 2023 2024 2025 5-year trend
SG&A Expense
445.53M 489.11M 498.06M 526.10M
Research & Development
87.14M 92.49M 96.66M 99.50M
Other SG&A
358.39M 396.61M 401.40M 426.61M
SGA Growth
+25.64% +9.78% +1.83% +5.63%
Other Operating Expense
- - - 900.00K
-
Unusual Expense
(35.21M) (67.56M) 68.04M 150.68M
EBIT after Unusual Expense
311.78M 348.27M 206.97M 102.25M
Non Operating Income/Expense
7.27M 5.05M 7.98M 15.93M
Non-Operating Interest Income
794.00K 3.41M 3.32M 3.89M
Equity in Earnings of Affiliates
- - (6.84M) 938.00K
-
Interest Expense
17.66M 14.67M 29.26M 19.72M
Interest Expense Growth
-21.68% -16.95% +99.50% -32.62%
Gross Interest Expense
17.66M 14.67M 29.26M 19.72M
Interest Capitalized
- - - -
-
Pretax Income
301.39M 338.66M 185.69M 98.46M
Pretax Income Growth
+103.40% +12.37% -45.17% -46.97%
Pretax Margin
+27.26% +29.79% +16.02% +8.07%
Income Tax
38.29M 53.22M 17.58M 25.06M
Income Tax - Current - Domestic
16.74M 72.56M 45.08M 64.99M
Income Tax - Current - Foreign
14.48M 10.45M 12.66M 11.22M
Income Tax - Deferred - Domestic
9.61M (31.24M) (32.86M) (50.74M)
Income Tax - Deferred - Foreign
(2.54M) 1.44M (7.30M) (416.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - (6.84M) 938.00K
-
Other After Tax Income (Expense)
(121.00K) (70.00K) (33.00K) (37.00K)
Consolidated Net Income
262.98M 285.37M 168.07M 73.36M
Minority Interest Expense
- - (8.95M) 179.00K
-
Net Income
271.93M 285.19M 168.07M 73.36M
Net Income Growth
+93.79% +4.88% -41.07% -56.35%
Net Margin Growth
+24.60% +25.09% +14.50% +6.02%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
271.93M 285.19M 168.07M 73.36M
Preferred Dividends
- - - -
-
Net Income Available to Common
271.93M 285.19M 168.07M 73.36M
EPS (Basic)
1.7334 1.8144 1.0657 0.4657
EPS (Basic) Growth
+91.45% +4.67% -41.26% -56.30%
Basic Shares Outstanding
156.88M 157.18M 157.71M 157.52M
EPS (Diluted)
1.6569 1.762 1.0454 0.4593
EPS (Diluted) Growth
+91.20% +6.34% -40.67% -56.06%
Diluted Shares Outstanding
164.12M 161.85M 160.77M 159.72M
EBITDA
377.63M 387.95M 386.72M 362.84M
EBITDA Growth
+11.86% +2.73% -0.32% -6.18%
EBITDA Margin
+34.16% +34.13% +33.37% +29.75%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 66.231
Number of Ratings 18 Current Quarters Estimate 0.459
FY Report Date 12 / 2025 Current Year's Estimate 2.011
Last Quarter’s Earnings 0.42 Median PE on CY Estimate N/A
Year Ago Earnings 1.92 Next Fiscal Year Estimate 2.252
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 15 14
Mean Estimate 0.46 0.57 2.01 2.25
High Estimates 0.49 0.60 2.07 2.44
Low Estimate 0.43 0.53 1.91 2.14
Coefficient of Variance 3.75 3.18 2.26 3.51

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 13
OVERWEIGHT 1 1 2
HOLD 5 5 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Bio-techne Corp. - TECH

Date Name Shares Transaction Value
Apr 8, 2025 Shane V. Bohnen SVP - General Counsel 3,941 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 8, 2025 Shane V. Bohnen SVP - General Counsel 3,194 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $54.86 per share 175,222.84
Apr 8, 2025 Shane V. Bohnen SVP - General Counsel 2,259 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Bio-Techne Corp. in the News

Foxconn, Wisconsin reach new deal on scaled back facility

Foxconn Technology Group, the world's largest electronics manufacturer, has reached a new deal with reduced tax breaks for its scaled back manufacturing facility in southeast Wisconsin, Gov. Tony Evers and the the company announced on Monday.